(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
Figure out how to Detect the Best Rooftop Substitution Choices- Mont Blanc road tunnel reopens to traffic after 15 weeks of repairs
- Colleges say foreign students feel 'unwelcome' in the U.S. amid big drop in international enrollment, new survey finds
- Heavenly Pastry Confrontation: Pick Your #1 Sweet Treat!
- A decade after Brazil’s deadly dam collapse, Indigenous peoples demand justice on the eve of COP30
- The Response to Independence from the rat race: Methodologies for Creating Financial momentum
- Tributes pour in for MIT professor Nuno Loureiro amid unresolved shooting case
- The most effective method to Refresh the Infotainment Framework in the Volvo XC40
- Experts who once backed 'shaken baby' science now fight to free imprisoned caregivers
